COST EFFECTIVENESS MODEL OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC) IN FRENCH SETTING

被引：0
|
作者：
de Gennes, Dubois C. [1 ]
Mazaleyrat, B. [2 ]
Alvarez, Sanchez J. [3 ]
Lueza, B. [4 ]
机构：
[1] Amaris, Levallois Perret, France
[2] Roche, Boulogne Billancourt, France
[3] F Hoffman La Roche Ltd, Basel, BS, Switzerland
[4] Amaris Consulting, Stockholm, Sweden
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB49
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ATEZOLIZUMAB IN ASSOCIATION WITH BEVACIZUMAB FOR PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC) USING A FRENCH REAL-WORLD EVIDENCE DATABASE
    Gaugain, L.
    Laurendeau, C.
    Gilberg, M.
    Mazaleyrat, B.
    Genestier, V
    VALUE IN HEALTH, 2022, 25 (01) : S96 - S96
  • [2] PRELIMINARY RESULTS OF A COST EFFECTIVENESS MODEL OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN FRANCE
    de Gennes, Dubois C.
    Mazaleyrat, B.
    Alvarez, Sanchez J.
    Cawston, H.
    VALUE IN HEALTH, 2020, 23 : S436 - S436
  • [3] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma: A cost-effectiveness analysis.
    Wang Wenjun
    Wang Jingjing
    Zhang Xin
    Wang Yikai
    Shi Juanjuan
    Jia Xiaoli
    Dang Shuangsuo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Cost-effectiveness of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
    Patel, Kishan
    Stein, Stacey
    Luther, Janki
    Huntington, Scott F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
  • [6] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
    Hoang, H. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
  • [7] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
    D'Alessio, Antonio
    Cammarota, Antonella
    Zanuso, Valentina
    Pressiani, Tiziana
    Personeni, Nicola
    Rimassa, Lorenza
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
  • [8] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [9] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Hongyu Gong
    Siew Chin Ong
    Fan Li
    Zhiying Weng
    Keying Zhao
    Zhengyou Jiang
    Cost Effectiveness and Resource Allocation, 21
  • [10] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Gong, Hongyu
    Ong, Siew Chin
    Li, Fan
    Weng, Zhiying
    Zhao, Keying
    Jiang, Zhengyou
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
12345